278 citations,
March 2013 in “Gut” In this study, 434 patients with inflammatory bowel disease (IBD) treated with anti-TNF-α antibodies were screened for psoriasiform skin lesions, with 21 (4.8%) developing such lesions. Smoking and increased body mass index were identified as significant predictors. Histological analysis revealed infiltrates of Th1 and Th17 cells in the lesions. Nine patients with severe lesions or anti-TNF-induced alopecia were treated with the anti-IL-12/IL-23 antibody ustekinumab, achieving a 100% response rate. The severity of lesions correlated with the number of IL-17A-expressing T cells. The study concluded that anti-IL-12/IL-23 antibody therapy is highly effective for treating these lesions.
60 citations,
September 2013 in “Alimentary Pharmacology & Therapeutics” Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.
49 citations,
January 2012 in “Dermatology” The document described 5 cases of anti-TNF-α induced psoriasiform eruptions with severe scalp involvement leading to inflammatory alopecia. Topical therapy was effective in only 1 case, while the other 4 required systemic therapy (methotrexate ± cyclosporine). Among these, 3 patients discontinued anti-TNF-α treatment, resulting in 2 achieving clear/almost clear status and 1 showing mild improvement; the fourth patient switched anti-TNF-α but continued to experience flare-ups. No scarring alopecia was observed in these cases. A review of 15 total cases in the literature indicated that 9 patients discontinued anti-TNF-α and 9 received systemic therapy, with 2 developing scarring alopecia. The study concluded that while some patients may respond to topical treatment, severe cases should consider anti-TNF-α suspension and systemic therapy to prevent scarring alopecia.
72 citations,
April 2011 in “The American Journal of Dermatopathology” Anti-TNF therapy can cause a unique type of hair loss that may get better with topical treatments without stopping the therapy.
9 citations,
May 2005 in “Expert Review of Clinical Immunology” Blocking interferon-gamma might help treat various autoimmune diseases.
May 2012 in “CRC Press eBooks” Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.
41 citations,
July 2015 in “Clinical and Experimental Dermatology” Psoriasis can cause temporary or permanent hair loss.
16 citations,
April 2014 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” A patient lost all their hair while on rheumatoid arthritis medication.
13 citations,
August 2019 in “Dermatologic therapy” Stopping adalimumab and starting methotrexate with topical treatments improved the woman's scalp psoriasis and hair regrew.
8 citations,
January 2015 in “World Journal of Gastroenterology” Hair loss is common in IBD patients, and some medications may lower the risk.
3 citations,
May 2021 in “JAAD case reports” Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.
2 citations,
October 2022 in “Current Allergy and Asthma Reports” Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
1 citations,
October 2015 in “The American journal of gastroenterology” Stopping infliximab and using strong topical steroids can regrow hair lost due to psoriasiform alopecia.
July 2024 in “Skin Appendage Disorders” Certain medications, including some immune drugs, contraceptives, and hair loss treatments, are often linked to hair loss.
15 citations,
March 2021 in “Journal of clinical medicine” Biologic treatments for Crohn's disease and ulcerative colitis can cause skin problems, and doctors should adjust treatment if these occur.
4 citations,
November 2013 in “Clinics in Dermatology” Experts don't fully agree on how to diagnose certain hair growth disorders and more research is needed to understand them better.
3 citations,
May 2018 in “Experimental Dermatology” Young HS patients often have other physical and mental health issues, and research on HS covers a wide range of topics including genetics, triggers, treatments, and the need for more data.
2 citations,
May 2016 in “Clínica e Investigación en Arteriosclerosis” Some skin conditions may increase the risk of heart disease, but are not yet included in cardiovascular prevention guidelines.
1 citations,
January 2019 in “Springer eBooks” Hidradenitis Suppurativa is a chronic skin condition best treated early with surgery for better outcomes and less recurrence.
August 2021 in “Research Square (Research Square)” Borneol Essential Oil could be a natural and safe acne treatment.
2 citations,
January 2014 in “Journal of clinical and investigative dermatology” Some drugs used to treat immune conditions may cause different types of hair loss.
1 citations,
September 2023 in “Rheumatology advances in practice” A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.
20 citations,
August 2019 in “Frontiers in immunology” Biologics show promise in treating various stubborn skin diseases, but more research and better reimbursement criteria are needed.
32 citations,
January 2012 in “Clinical & Developmental Immunology” Targeting CD200 could be a new treatment for rheumatoid arthritis.
65 citations,
June 2020 in “Stem Cell Research & Therapy” Certain immune system proteins are important for skin healing but can cause problems if there are too many of them.
10 citations,
October 2010 in “Hepatology” Certain liver diseases respond well to specific treatments and have varying risks for liver cancer.
7 citations,
October 2005 in “British Journal of Dermatology” Etanercept improved symptoms of a specific type of psoriatic arthritis in a patient who didn't respond to other treatments.
February 2008 in “Medical & surgical dermatology” Some treatments like topical oxygen and stem cells show promise for wound healing and hair growth, but evidence for modern dressings over traditional ones is limited.
21 citations,
September 2010 in “Archives of Dermatology” A woman developed psoriasis after taking certolizumab pegol, improving after stopping the drug and starting other treatments.
4 citations,
June 2013 in “The Journal of Rheumatology” The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.